Literature DB >> 4000684

Potentiation of morphine antinociception by monoamine reuptake inhibitors in the rat spinal cord.

Yetunde O Taiwo1, Annette Fabian, Christopher J Pazoles, Howard L Fields.   

Abstract

Potentiation of the antinociceptive effects of morphine by the tricyclic antidepressants was assayed in awake restrained rats using the tail-flick test. Intrathecally administered amitriptyline, desipramine or sertraline at doses that had no effect themselves (25-30 micrograms) potentiated a subthreshold parenteral dose of morphine (0.5 mg/kg). The morphine potentiating effect of amitriptyline was prevented by prior administration of parachlorophenylalanine (PCPA). This effect of PCPA was not restored by 5-hydroxytryptophan (5-HTP) but was restored when the animals were left for 14 days to replete. The morphine potentiating effects of amitriptyline, desipramine and sertraline were blocked by intrathecal administration of low doses of the serotonin antagonist methysergide and the alpha-adrenergic antagonists yohimbine and phentolamine but not by the beta-adrenergic antagonist propranolol. The results are consistent with the hypothesis that the potentiation of morphine's antinociceptive effect by tricyclic antidepressants depends on activation of both spinopetal serotonin and adrenergic neurons.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4000684     DOI: 10.1016/0304-3959(85)90162-9

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  14 in total

1.  Interaction of opioids with antidepressant-induced antinociception.

Authors:  F Sierralta; G Pinardi; M Mendez; H F Miranda
Journal:  Psychopharmacology (Berl)       Date:  1995-12       Impact factor: 4.530

2.  Altered antinociceptive efficacy of tramadol over time in rats with painful peripheral neuropathy.

Authors:  Aldric Hama; Jacqueline Sagen
Journal:  Eur J Pharmacol       Date:  2006-12-01       Impact factor: 4.432

3.  Activation of serotonergic neurons in the raphe magnus is not necessary for morphine analgesia.

Authors:  K Gao; D O Chen; J R Genzen; P Mason
Journal:  J Neurosci       Date:  1998-03-01       Impact factor: 6.167

4.  Evidence for crosstolerance to the analgesic effects between morphine and selective alpha 2-adrenoceptor agonists.

Authors:  C Post; T Archer; B G Minor
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

5.  A greater role for the norepinephrine transporter than the serotonin transporter in murine nociception.

Authors:  F S Hall; J M Schwarzbaum; M T G Perona; J S Templin; M G Caron; K-P Lesch; D L Murphy; G R Uhl
Journal:  Neuroscience       Date:  2010-12-01       Impact factor: 3.590

6.  Intrathecal administration of doxepin attenuated development of formalin-induced pain in rats.

Authors:  J Wordliczek; M Banach; D Labuz; B Przewlocka
Journal:  J Neural Transm (Vienna)       Date:  2005-03-23       Impact factor: 3.575

Review 7.  Pharmacological profiles of alpha 2 adrenergic receptor agonists identified using genetically altered mice and isobolographic analysis.

Authors:  Carolyn A Fairbanks; Laura S Stone; George L Wilcox
Journal:  Pharmacol Ther       Date:  2009-04-23       Impact factor: 12.310

8.  Noradrenergic and opioidergic influences on the antinociceptive effect of clomipramine in the formalin test in rats.

Authors:  M Ansuategui; L Naharro; M Feria
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

9.  Antidepressant Use in Chronic Pain Management: Is There Evidence of a Role for Duloxetine?

Authors:  Raphael J. Leo; Robert L. Barkin
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2003-06

10.  Experience and challenges presented by a multicenter crossover study of combination analgesic therapy for the treatment of painful HIV-associated polyneuropathies.

Authors:  Taylor Harrison; Sachiko Miyahara; Anthony Lee; Scott Evans; Barbara Bastow; David Simpson; Ian Gilron; Robert Dworkin; Eric S Daar; Linda Wieclaw; David B Clifford
Journal:  Pain Med       Date:  2013-04-08       Impact factor: 3.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.